🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase III

Metabolic & obesity programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
227

Quick answer

Metabolic & obesity Phase III programs: NovaPharmaNews indexes 227 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 5 of 5

  1. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Diabetes Mellitus

    phase 3 mab completed

    1 trial

  2. VX-880

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetes Mellitus, Type 1

    phase 3 mab active

    1 trial

  3. VX-880 solution for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial

  4. Vildagliptin

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  5. Vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  6. Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  7. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  8. Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets

    Istituto Gentili S.r.l.

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

    phase 3 small molecule active

    1 trial

  9. aflibercept 8 mg PFS

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    phase 3 small molecule completed

    1 trial

  10. albiglutide + insulin glargine

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 mab completed

    1 trial

  11. biphasic insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  12. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  13. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  14. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  15. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  16. cagrilintide, Placebo, cagrilintide, cagrilintide, cagrilintide

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  17. cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  18. candesartan

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  19. candesartan

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  20. candesartan cilexetil

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  21. evogliptin

    Dong Wang

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. exenatide once weekly

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  23. fluocinolone acetonide

    ANI PHARMACEUTICALS INC

    Diabetic Macular Edema

    phase 3 small molecule completed

    3 trials

  24. insulin degludec

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  25. linagliptine 5 mg

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  26. liraglutide

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  27. lixisenatide AVE0010

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  28. lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 3 small molecule terminated

    1 trial

  29. muraglitazar

    Bristol-Myers Squibb

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  30. ofloxacin

    ABEONA THERAPEUTICS INC.

    Diabetic Foot Ulcers

    phase 3 small molecule completed

    2 trials

  31. pioglitazone

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    1 trial

  32. placebo to match albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  33. rosiglitazone

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule terminated

    1 trial

  34. semaglutide

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    4 trials

  35. survodutide

    Boehringer Ingelheim

    Obesity

    phase 3 other active

    1 trial

Frequently asked questions

How many metabolic & obesity Phase III programs exist?

227 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.